Scholarlink

Background <p>Crohn’s disease is a chronic inflammatory condition that can relapse and can impact any part of the digestive tract. Janus kinase (JAK) inhibitors, like Filgotinib, have surfaced as a promising treatment option. This meta-analysis evaluates its dose-dependent effects (100&#xa0;mg or 200&#xa0;mg) in moderate-to-severe cases.</p> Methods <p>A comprehensive search was conducted in PubMed, CENTRAL, Web of Science, Scopus, and EMBASE up to March 2025. Risk ratio (RR) was used for dichotomous outcomes, with 95% confidence intervals (CI). PROSPERO ID: CRD420251032985.</p> Results <p>Four RCTs with 1681 patients were included. Filgotinib 200&#xa0;mg compared to placebo had a higher rate of mucosal remission at 24 to 58&#xa0;weeks (wk) (14.9% vs 6%, RR = 2.51, 95% CI [1.06:5.95], <i>P</i> = 0.0370),&#xa0;two-item patient’sreported outcome (PRO2) clinical remission at 10 wk (35.7% vs 22.5%, RR = 1.48, 95% CI [1.21:1.81], <i>P</i> = 0.0002), and&#xa0;Crohn’s Disease Activity Index (CDAI) clinical remission at 10 wk (33.4% vs 17.8%, RR = 1.77, 95% CI [1.42:2.21], <i>P</i> &lt; 0.0001). However, there was no significant difference between Filgotinib 100&#xa0;mg and placebo in rates of CDAI clinical remission at 10 wk (<i>P</i> = 0.7490) and mucosal remission at 24 to 58 wk (<i>P</i> = 0.5850). In both doses, there was no significant difference in total treatment adverse events (TEAEs) at 20 to 58 wk (<i>P</i> = 0.4576,<i> P</i> = 0.2354) and serious TEAEs at 20 to 58 wk (<i>P</i> = 0.992,<i> P</i> = 0.2354).</p> Conclusions <p>Filgotinib 200&#xa0;mg demonstrated superior short-term clinical benefits and medium-term mucosal remission compared to placebo in moderate-to-severe CD. However, Filgotinib 100&#xa0;mg showed no significant efficacy. Both doses have acceptable safety profiles, necessitating further long-term multicenter RCTs.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dose-dependent efficacy and safety of Filgotinib in moderate to severe Crohn’s disease: a grade-assessed systematic review and meta-analysis of randomized controlled trials

  • 期刊论文

  • 发表日期：

    2025年8月2日

查看全文
  • Mohamed S. Elgendy,
  • Ahmed Raza,
  • Mohamed Rifai,
  • Wajeeh Ur Rehman,
  • Ahmed Emara,
  • Muhammad Haris Khan,
  • Ayiz Jan,
  • Muhammad Younas,
  • Anum Nawaz,
  • Ubaid Khan

摘要

Background

Crohn’s disease is a chronic inflammatory condition that can relapse and can impact any part of the digestive tract. Janus kinase (JAK) inhibitors, like Filgotinib, have surfaced as a promising treatment option. This meta-analysis evaluates its dose-dependent effects (100 mg or 200 mg) in moderate-to-severe cases.

Methods

A comprehensive search was conducted in PubMed, CENTRAL, Web of Science, Scopus, and EMBASE up to March 2025. Risk ratio (RR) was used for dichotomous outcomes, with 95% confidence intervals (CI). PROSPERO ID: CRD420251032985.

Results

Four RCTs with 1681 patients were included. Filgotinib 200 mg compared to placebo had a higher rate of mucosal remission at 24 to 58 weeks (wk) (14.9% vs 6%, RR = 2.51, 95% CI [1.06:5.95], P = 0.0370), two-item patient’sreported outcome (PRO2) clinical remission at 10 wk (35.7% vs 22.5%, RR = 1.48, 95% CI [1.21:1.81], P = 0.0002), and Crohn’s Disease Activity Index (CDAI) clinical remission at 10 wk (33.4% vs 17.8%, RR = 1.77, 95% CI [1.42:2.21], P < 0.0001). However, there was no significant difference between Filgotinib 100 mg and placebo in rates of CDAI clinical remission at 10 wk (P = 0.7490) and mucosal remission at 24 to 58 wk (P = 0.5850). In both doses, there was no significant difference in total treatment adverse events (TEAEs) at 20 to 58 wk (P = 0.4576, P = 0.2354) and serious TEAEs at 20 to 58 wk (P = 0.992, P = 0.2354).

Conclusions

Filgotinib 200 mg demonstrated superior short-term clinical benefits and medium-term mucosal remission compared to placebo in moderate-to-severe CD. However, Filgotinib 100 mg showed no significant efficacy. Both doses have acceptable safety profiles, necessitating further long-term multicenter RCTs.

Graphical abstract